A new study shows that epitranscriptomics, or chemical regulation of gene expression at the RNA level, determines whether ...

These are heady days for PharmaEssentia, a biotech that got its start 23 years ago in Taiwan, went public 10 years later and ...

Takeda Pharmaceutical’s Mimrylo is now approved for treating polycythemia vera, a rare blood cancer with limited therapeutic ...

FDA approves BESREMi for adults with essential thrombocythemia, offering a new treatment option for people living with this ...

Joe Palmquist, the former managing editor and longtime sports editor of The Spokesman-Review, died Saturday from a lung disease following a bone marrow transplant last November. His services ...

Discover essential information about Chronic Lymphocytic Leukemia (CLL), its diagnosis, symptoms, and treatment options in ...

A Korean dating show following young people who have survived cancer and rare diseases as they seek new love has become a ...

From today, the Australian government will expand Pharmaceutical Benefit Scheme (PBS) access to the drug Keytruda for three ...

Karyopharm Therapeutics Inc. ( KPTI) announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. FDA seeking Accelerated Approval for XPOVIO in combination with Ruxolitinib ...

In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at ...

PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446) today announced the U.S. Food and Drug Administration (FDA) has approved BESREMi® (ropeginterferon alfa-2b-njft) ...

The EXODUS H-600 offers an automated, scalable approach to exosome isolation, which should reduce hands-on processing and ...